Home » Market News » DirectorsTalk Highlights » Oxford Biodynamics Business
Oxford BioDynamics

Oxford Biodynamics Business

Our proprietary technology platform enables pharmaceutical companies to accelerate and improve the rate of drug discovery and development

Through the development of epigenetic biomarkers, EpiSwitch™ can help pharmaceutical companies to:

  • REDUCE the risk, cost and time to market for therapeutic development programmes
  • GAIN significant insights into disease mechanisms, to support the personalisation of medicine
  • PERSONALISE therapeutics to patients, to ensure better clinical outcomes

Oxford Biodynamics PLC (LON:OBD) was spun out from Oxford University in June 2007 with the aim of translating fundamental scientific advances into a commercialised platform technology and a new generation of biomarkers for cancer, ALS and other diseases.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.